Get started
Author

Karin Hägerbrand

Observed names: Hägerbrand, Karin, K Hägerbrand, Karin Hagerbrand
ORCID: 0009-0004-5662-6990
Observed ORCID: 0009-0004-5662-6990
OpenAlex ID: A5068228532
IRF4 Transcription-Factor-Dependent CD103+CD11b+ Dendritic Cells Drive Mucosal T Helper 17 Cell Differentiation
2013 · Emma K. Persson, Heli Uronen-Hansson, et al. · Immunity · 622
PDF
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
2019 · Anne Månsson Kvarnhammar, Niina Veitonmäki, et al. · Journal for ImmunoTherapy of Cancer · 122
PDF
MyD88 Signaling Regulates Steady-State Migration of Intestinal CD103+ Dendritic Cells Independently of TNF-α and the Gut Microbiota
2015 · Karin Hägerbrand, Jessica Westlund, et al. · The Journal of Immunology · 45
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
2021 · Karin Enell Smith, Adnan Deronic, et al. · Expert Opinion on Biological Therapy · 40
PDF
CD103+CD11b+ mucosal classical dendritic cells initiate long-term switched antibody responses to flagellin
2017 · A Flores-Langarica, K Müller Luda, et al. · Mucosal Immunology · 40
PDF
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
2022 · Karin Hägerbrand, Laura Varas, et al. · Journal for ImmunoTherapy of Cancer · 34
PDF
Next-generation CD40 agonists for cancer immunotherapy
2024 · Hampus Andersson, Barnabas Nyesiga, et al. · Expert Opinion on Biological Therapy · 32
PDF
Transcriptional profiling demonstrates altered characteristics of CD8 + cytotoxic T‐cells and regulatory T‐cells in TP53 ‐mutated acute myeloid leukemia
2022 · Milad Abolhalaj, Viktor Sincic, et al. · Cancer Medicine · 18
IL‐18Rα‐deficient CD4+ T cells induce intestinal inflammation in the CD45RBhi transfer model of colitis despite impaired innate responsiveness
2016 · Petra Holmkvist, Lieneke Pool, et al. · European Journal of Immunology · 11
PDF
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties
2024 · Barnabas Nyesiga, Mattias Levin, et al. · mAbs · 9
PDF
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
2023 · Hampus Andersson, Aastha Sobti, et al. · Cells · 8
PDF
Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes
2024 · Viktor Sincic, Ken F. Arlenhold, et al. · Cells · 5
PDF
858 A bispecific antibody targeting CD40 and EpCAM induces superior anti-tumor effects compared to the combination of the monospecific antibodies
2020 · Peter Ellmark, Karin Hägerbrand, et al. · Journal for ImmunoTherapy of Cancer · 5
Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform
2025 · Barnabas Nyesiga, Karin Hägerbrand, et al. · Drug Delivery · 4
PDF
Kick-starting tumor specific T cell priming & targeting the tumor microenvironment using CD40 targeting bispecific antibodies
2022 · Karin Hägerbrand, Peter Ellmark · Immuno Oncology Insights · 2
751 Neo-X-Prime bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigen and induce superior anti-tumor responses compared to CD40 mAb
2021 · Karin Hagerbrand, Mattias Levin, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al. · Cancer Immunology Research · 1
PDF
837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro
2023 · Ida Uddbäck, Sara Fritzell, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Abstract 3623: The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
2018 · Niina Veitonmäki, Mia Thagesson, et al. · Cancer Research · 1
Data from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S1 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S17 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S15 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Table S2 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S7 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Works count: 60
Citation count: 1,002
H-index: 9
I10-index: 9
Year
Topic
Type